There may soon be a new approach to treat hard-to-control high blood pressure | AI News Digest
AstraZeneca's experimental drug, Baxdrostat, shows promise in treating hard-to-control high blood pressure, potentially revolutionizing treatment options. In a recent trial, nearly 40% of participants taking Baxdrostat achieved healthy blood pressure levels, compared to less than 20% on a placebo. This new approach targets aldosterone, a hormone linked to high blood pressure, offering hope for patients who have not responded well to existing medications. Researchers presented these findings at the European Society of Cardiology Congress 2025. If approved, Baxdrostat could become a key treatment for resistant hypertension, which affects 1 in 10 individuals. Experts emphasize the need for further studies to identify the best candidates for this medication.
